AU2299099A - Antibodies against human vegf receptor kdr - Google Patents

Antibodies against human vegf receptor kdr

Info

Publication number
AU2299099A
AU2299099A AU22990/99A AU2299099A AU2299099A AU 2299099 A AU2299099 A AU 2299099A AU 22990/99 A AU22990/99 A AU 22990/99A AU 2299099 A AU2299099 A AU 2299099A AU 2299099 A AU2299099 A AU 2299099A
Authority
AU
Australia
Prior art keywords
antibodies against
against human
vegf receptor
human vegf
receptor kdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22990/99A
Inventor
Hideharu Anazawa
Nobuo Hanai
Mikito Ito
Masabumi Shibuya
Akeo Shinkai
Kenya Shitara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of AU2299099A publication Critical patent/AU2299099A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU22990/99A 1998-02-04 1999-02-04 Antibodies against human vegf receptor kdr Abandoned AU2299099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP10-23388 1998-02-04
JP2338898 1998-02-04
PCT/JP1999/000478 WO1999040118A1 (en) 1998-02-04 1999-02-04 Antibodies against human vegf receptor kdr

Publications (1)

Publication Number Publication Date
AU2299099A true AU2299099A (en) 1999-08-23

Family

ID=12109147

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22990/99A Abandoned AU2299099A (en) 1998-02-04 1999-02-04 Antibodies against human vegf receptor kdr

Country Status (2)

Country Link
AU (1) AU2299099A (en)
WO (1) WO1999040118A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3850299A (en) * 1998-05-20 1999-12-06 Kyowa Hakko Kogyo Co. Ltd. Vegf activity inhibitors
IL144578A0 (en) * 1999-01-29 2002-05-23 Imclone Systems Inc Antibodies specific to kdr and uses thereof
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
KR100816572B1 (en) 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Anti-VEGF antibody and a pharmaceutical composition comprising the same
AU784187B2 (en) * 1999-09-30 2006-02-16 Kyowa Hakko Kogyo Co. Ltd. Human type complementarity determining region transplantation antibody against ganglioside GD3 and derivatives of antibody against ganglioside GD3
DK1548032T3 (en) 2002-09-12 2009-08-17 Oncotherapy Science Inc KDR peptides and vaccines containing them
CN101102791B (en) 2004-11-18 2011-12-14 英克隆有限责任公司 Antibodies against vascular endothelial growth factor receptor-1
EP2136831B1 (en) 2007-03-02 2012-09-12 The Cleveland Clinic Foundation Anti-angiogenic peptides
TWI436775B (en) 2007-08-24 2014-05-11 Oncotherapy Science Inc Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent
ES2572356T3 (en) 2007-11-09 2016-05-31 Peregrine Pharmaceuticals Inc Compositions of antibodies directed against VEGF and procedures
US20110200612A1 (en) 2008-06-30 2011-08-18 Michael Schuster Treatment of eye diseases and excessive neovascularization using combined therapy
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
CN109072241A (en) 2016-02-08 2018-12-21 维特里萨医疗公司 With the improved composition of vitreous half-life and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM379394A0 (en) * 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - i
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
DE19638745C2 (en) * 1996-09-11 2001-05-10 Schering Ag Monoclonal antibodies against the extracellular domain of the human VEGF receptor protein (KDR)

Also Published As

Publication number Publication date
WO1999040118A1 (en) 1999-08-12

Similar Documents

Publication Publication Date Title
AU1462300A (en) Human pan-hcv human monoclonal antibodies
EP1169352A4 (en) Erythropoietin receptor antibodies
AU7445900A (en) Novel hemopoietin receptor protein, nr12
AU4935000A (en) Antibodies
AU5095000A (en) Receptor interacting protein rip3
AU3453499A (en) Human oxidized ldl receptor
AU2299099A (en) Antibodies against human vegf receptor kdr
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
GB9903767D0 (en) Receptor assay
AU5441000A (en) Human monoclonal antibody
EP1088831A4 (en) Novel hemopoietin receptor proteins
AU7132898A (en) Edg-1-like receptor
IL146151A0 (en) Human-g-protein receptor
AU1296899A (en) Phenyl-alkyl-imidazoles as h3 receptor antagonists
IL148266A0 (en) Apo-2 receptor antibodies
AU1744700A (en) Human neurotensin subtype 2 receptor
EP1151006A4 (en) Human g protein coupled receptor
AU3668499A (en) Human receptor molecules
ZA9711456B (en) VEGF-B/receptor complex and uses thereof.
AU6035398A (en) Human c5a-like receptor
AU2452301A (en) Protein methylarginine-specific antibodies
AU4483500A (en) Human membrane-associated proteins
AU4849299A (en) Human emr1-like g protein coupled receptor
AU2574801A (en) Selective iGLUR5 receptor antagonists
AU2659799A (en) Human receptor proteins

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase